IDYA•benzinga•
The FDA Clears Ideaya Biosciences' Investigational New Drug Application To Initiate A Phase 1 Trial To Evaluate IDE849 (SHR-4849), A Potential First-in-class Delta-like Ligand 3-targeting Topo-i-payload Antibody Drug Conjugate Program, In Solid Tumors
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 6, 2025 by benzinga